A native Canadian firm, Optimi Health Corp. (OPTI:CNX), makes synthetic formulations for transformative human experiences as well as natural, scaleable, and affordable psychedelic and functional mushrooms. The organization is included on Health Canada’s list of authorized suppliers for the Special Access Program (SAP), which gives medical professionals emergency access to Schedule 3 prohibited medications like psilocybin.
On September 8, Optimi Health (OPTI:CNX) said that the largest legal psilocybin harvest in Canadian history had been completed. As a result, health Canada has permitted the business to produce and sell natural psilocybin of EU-GMP quality as well as other psychedelics, such as MDMA and functional mushrooms, with a focus on the health and wellness sectors.
The business said its investment in environmental controls and cultivation operations at cutting-edge facilities led to a commercial harvest yield of more than 150 kg of Panaeolus cyanescens and Psilocybe cubensis.
The top-ranked psilocybin genebank of Optimi (OPTI:CNX)is used to generate all of the Company’s mushroom products. They are grown in clean rooms that follow EU-GMP rules to ensure sterile culture. After harvest, they go through almost 300 different analytical tests.
According to Justin Kirkland, Chief Science Officer of Optimi Health (OPTI:CNX) “Our mushrooms are among of the most tested goods on the earth as we span the borders of Pharmaceutical, Agriculture, Botanical, and Food testing quality assays”. This yield, he said, “gives us the size and capability we need to progress our analytical timetable and build our product pipeline.”
Optimi (OPTI:CNX) will start distributing harvested quantities after they have undergone rigorous internal and external testing to meet the company’s strict product specifications and quality assurance standards. This is done in order to fulfill supply agreements that have recently been made with numerous industry partners and accredited research organizations all over the world.
To guarantee that natural psilocybin doesn’t degrade too much, any surplus inventory from the harvest will be kept in Optimi’s (OPTI:CNX) Level 8 security vault.
The revenues will be used by Optimi Health to complete its natural-origin psilocybin product offerings this autumn. The Company will also utilize the mushrooms to improve its on-site extraction techniques. To compile the necessary human safety data in healthy Canadians and maybe patients with depression, anxiety, and PTSD, the business aims to deliver several planned Phase 1 and 2 clinical studies.
The Company’s worldwide innovation goal includes bringing a safe, legally approved supply of psilocybin products beyond encapsulated biomass to the market.
The Chief Operations Officer of Optimi, Bryan Safarik, says that both the quality and the amount of the product were better than expected.
Safarik said, “We can reliably grow psilocybin-containing mushrooms at a much higher potency to make the most of the psilocybin that naturally grows in the mushroom.”
By managing and recording all of the inputs digitally, these cutting-edge controls are an important point of differentiation for what we have to offer the worldwide market. We can make a lot more natural psilocybin per square foot than a typical black market grows, because the more potent it is, the less biomass is needed to make the amount of pure psilocybin API that is needed. He said that more psilocybin produced in a smaller area generates more money per square foot.
To prevent significant deterioration of the natural psilocybin, any extra merchandise from the harvest will be securely kept in a Level 8 Security Vault owned by Optimi (OPTI:CNX).
The product will be utilized by Optimi Health (OPTI:CNX) to complete its organically derived psilocybin offerings this autumn. The company will also utilize the mushrooms to refine its on-site extraction techniques further. In addition, the company is striving to provide a number of planned phase 1 and phase 2 clinical studies to gather the necessary human safety data in Canadians in good health and, subsequently, in patients with depression, anxiety, and PTSD.
The company’s worldwide innovation strategy depends on supplying the market with psilocybin products that are secure and authorized by the federal government, beyond encapsulated biomass.
In addition, biomass from this harvest is intended for use in demonstrating the stability and accuracy of dosing for patients who request access to natural psilocybin mushrooms. On May 11, Optimi Labs announced the expansion of its on-site analytical laboratory, which allows the company to measure consistency in its products while it begins to build out proprietary formulations, extracts, and its product catalog, beginning with the recently launched BLUE SERENITY.
The following mushroom strains that contain psilocybin are part of the harvest. They consist of Samui, Koh, B Plus, Malabar, envied penis, Burma, Indigo Pulaski
Optimi Health Enters Into Its First-Ever Agreement With Avida Global for the Export of Mushrooms.
On September 7, Optimi Health (OPTI:CNX) said that it had entered into a partnership with Avida Global, a private UK firm that produces premium health and wellness goods for the global medical and health sectors, including nutraceuticals and medicinal cannabis oils.
A company created with the aim of providing scalable psychedelic formulations for transformative human experiences. Its mission is to be the world’s most dependable and compassionate provider of safe pharmaceutical goods. The biggest psilocybin and MDMA producer in North America, Optimi Health (OPTI:CNX) grows its drugs at two locations in Princeton, British Columbia, totaling 20,000 square feet.
in its first major international distribution agreement, Optimi Health (OPTI:CNX) will provide Avida with a variety of Optimi Life functional mushroom supplement formulations. The Company’s manufacturing and white-labeling branch, Avida Labs, will market the supplements all over the globe to clients and business partners.
The functional mushroom products from Optimi Health (OPTI:CNX) will only be offered by Avida in the UK, EU, Switzerland, India, Japan, Indonesia, Thailand, and Israel.
The agreement’s conditions also permit the potential sale of psilocybin mushrooms using the same distribution channels. This is done to adapt to the shifting demands of global markets.
The worldwide agreement with Optimi Health (OPTI:CNX) represents a significant advancement for Avida in the area of plant-based therapeutics. Paul Parkinson reported that the Managing Director and Head of UK Operations of Avida Global agreed that it would benefit both businesses and increase their exposure.
Featured Image- Megapixl @ Eskymaks
